NCT03412565 2025-04-29A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensJanssen Research & Development, LLCPhase 2 Completed265 enrolled 21 charts 3 FDA
NCT02953678 2021-11-24A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)Incyte CorporationPhase 2 Completed71 enrolled 24 charts 1 FDA